Postdiagnosis Change in Bodyweight and Survival After Breast Cancer Diagnosis by Bradshaw, Patrick T. et al.
POST-DIAGNOSIS CHANGE IN BODYWEIGHT AND SURVIVAL
AFTER BREAST CANCER DIAGNOSIS
Patrick T. Bradshaw1, Joseph G. Ibrahim2, June Stevens1,3, Rebecca Cleveland3, Page E.
Abrahamson1, Jessie A. Satia1,3,†, Susan L. Teitelbaum4, Alfred I. Neugut5, and Marilie D.
Gammon1
1Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill,
NC, 27599
2Department of Biostatistics, School of Public Health, University of North Carolina, Chapel Hill,
NC, 27599
3Department of Radiology, School of Medicine, University of North Carolina, Chapel Hill, NC,
27599
4Department of Community and Preventive Medicine, Mount Sinai School of Medicine, New York,
NY 10029
5Department of Medicine, College of Physicians and Surgeons, and Department of Epidemiology,
Mailman School of Public Health, Columbia University, New York, NY 10032
Abstract
Background—Weight gain after diagnosis is common among women with breast cancer, yet
results have been inconsistent among the few studies examining its effects on survival.
Methods—We examined the effects of weight gain on mortality among a cohort of 1,436 women
diagnosed with a first primary breast cancer in 1996–1997, on Long Island, NY. Subjects were
interviewed soon after diagnosis and again after approximately 5 years. Weight was assessed at
each decade of adult life; one year before, at and one year after diagnosis; and at the time of
follow-up. Mortality through the end of 2005 was assessed using the National Death Index.
Proportional hazards regression was used while employing a selection model to account for
missing data.
Results—Compared with women who maintained their pre-diagnosis weight (+/− 5%), those
who gained more than 10% after diagnosis had worse survival (hazard ratio [HR]= 2.67; [95%
credible interval=1.37–5.05]. The effect was more pronounced during the first 2 years after
diagnosis (>5% gain, all-cause mortality in the first 2 years, HR = 5.87 [0.89 – 47.8] compared
with after 2 years (1.49 [0.85 – 2.57]); among women overweight before diagnosis (overweight
women, all-cause HR = 1.91 [0.91 – 3.88] compared with ideal-weight women, 1.39 [0.62 –
3.01)]; and for women who had gained at least 3 kilograms over adulthood before diagnosis (>= 3
kg gain before diagnosis 1.80 [0.99 – 3.26 compared with < 3 kg gain before diagnosis 1.07 [0.30
– 3.37].
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Conclusions—These results highlight the importance of weight maintenance for women after
breast cancer diagnosis.
For the more than 2 million female breast cancer survivors in the United States,1 it is
important to identify modifiable factors that may improve survival. Of particular interest is
the effect on survival of changes in body size after diagnosis, because weight gain among
women with breast cancer is often observed in response to treatment with chemotherapy, as
well as among women of younger age, women with lower pre-diagnosis body size, women
who are premenopausal, and women who present with later disease stage at diagnosis.2–7
Higher levels of adipose tissue are associated with greater circulating levels of hormones
such as estrogen, insulin and related growth factors, which increase proliferation of
mammary cells and are associated with breast carcinogenesis.8–10
Body size at or before diagnosis4 has been related to survival, but whether weight change
after diagnosis affects survival has been studied less frequently and with inconsistent
results.4,11–14 Furthermore, most previous studies have not employed longitudinal measures
of post-diagnosis weight change, and thus have been unable to examine whether the effect
may vary over time. The effect of changes in body size near diagnosis is a critically under-
addressed issue in survivorship research. Of the few studies that have addressed this issue,
most limit their approach in several key ways. First, most previous investigations have
assessed weight change only once after diagnosis; multiple measurements after diagnosis
times would help to elucidate the critical window of exposure in which weight change might
affect survival. Second, the study populations in previous analyses have been limited to
survivors 2 or more years post-diagnosis (often much more); this approach creates cohorts
biased in their tendency to survive, which again fails to account for the entire survivorship
experience.
A recent report from our group showed that weight gain after diagnosis was associated with
greater all-cause and breast cancer-specific mortality,15 among a cohort of women
interviewed shortly after diagnosis and followed for approximately 9 years. The primary
purpose of that manuscript was to describe an analytic method developed to account for
missing covariate data in survival analysis. That report did not address several important
issues regarding how the effect of weight change on survival may vary over time, or how the
effect may be confounded by, or vary by, pre-diagnosis body size characteristics. Here we
apply that method to examine the effect of post-diagnosis weight change over time on
survival after breast cancer diagnosis in a large, population-based cohort of women
diagnosed with breast cancer in 1996–1997 on Long Island, New York.
Methods
We used data from the Long Island Breast Cancer Study Project, which was initiated as a
population-based case-control study16 and continued as a follow-up of the cohort of case
women. The study was approved by the Institutional Review Board of participating
institutions.
Study Population
Cases were English-speaking adult women with a first primary in situ or invasive breast
cancer diagnosed between 1 August 1996 and 31 July 1997, from Nassau and Suffolk
counties in New York. Potentially eligible subjects were identified through participating
hospitals, and their physicians were contacted to confirm the diagnosis and obtain
permission to contact the patients for participation in the study. A total of 1,508 eligible
cases (82%) signed informed consent in person and completed the baseline questionnaires
an average of 3 months after diagnosis.16
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At baseline, 94 case women declined to be contacted at a later date for participation in the
follow-up. For the remaining cases, they or their proxy were contacted approximately 5
years after diagnosis of the first primary breast cancer. Of the 1,414 women who initially
agreed to participate, 60 subsequently declined when contacted by mail, 65 declined when
contacted by telephone, 18 declined due to illness, 22 were unable to complete the interview,
55 were lost to follow-up, and 96 were deceased with no identifiable proxy to complete the
interview. Of the remaining 1,098 subjects for whom informed consent was obtained by
telephone, 65 were omitted because they provided information only about their first course
of treatment for their first primary breast cancer. Ultimately 1,033 case subjects completed
the follow-up interview,17 of which about 8% were with the proxy. The follow-up
questionnaire included ascertainment of information similar to that gathered in the baseline
questionnaire,16 but relevant to the time period since diagnosis.
Outcome Assessment
Date and cause of death were determined through the National Death Index (NDI),18 a
centralized database of death records maintained by the National Center for Health
Statistics, which is considered the standard source of mortality data for epidemiologic
research.19 For deceased women we constructed two indicators: (1) breast cancer- specific
mortality (any breast cancer-related death, International Classification of Disease code 174.9
or C-50.9); and (2) all-cause mortality (death from any cause). Of the 1,508 cases from the
parent study, there were 308 deaths as of 31 December 2005, with just over half (n=164)
attributed to breast cancer.
Body Size Assessment
The baseline questionnaire16 assessed self-reported height in inches and body weight in
pounds at age 20 years and at 1 year prior to date of diagnosis. It also included assessments
of weight in pounds by decade of life from 20 years through 70 years of age. The follow-up
questionnaire included assessments of self-reported height and body weight in pounds at
diagnosis, one year after diagnosis and at the time of the follow-up interview (or one year
before death for deceased subjects for whom the questionnaire was completed by proxy).
This yielded three assessments of body size at and after diagnosis.
Percent change in body weight was calculated from the year prior to diagnosis to diagnosis,
1-year after diagnosis, and the time of follow-up interview as 100*(weight at later
measurement - weight one year before diagnosis)/weight one year before diagnosis.
We categorized weight change as >5% loss; maintained within (plus or minus) 5%; 5%–
10% gain; and greater than 10% weight gain. These categories were selected for comparison
with other reports,11 and they correspond to weight management recommendations aimed at
cancer patients.20 To avoid small counts within strata when assessing effect modification,
we combined the upper two categories of weight gain. Other body-size variables included
body mass index (BMI) 1 year before diagnosis (<25 kilograms/meters2 (kg/m2), 25–30 kg/
m2 and >=30 kg/m2) and adult weight change, from age 20 years to 1 year before diagnosis
(>3 kg loss, maintenance within 3 kg, and >3 kg gain). These categorizations reflect those
used in previous analyses of the Long Island Breast Cancer Project.21
Covariates
Structured questionnaires were administered by trained interviewers at baseline16 and at
follow-up. Information collected included sociodemographic characteristics, select clinical
characteristics (including first course of treatment for the first primary breast cancer), and
known and suspected risk and prognostic factors for breast cancer.
Bradshaw et al. Page 3













For case women who signed a medical record release form at baseline (97.7%), tumor stage
and estrogen and progesterone receptor (ER/PR) status of the first primary breast cancer
were ascertained from the medical records. At the follow-up, signed medical record release
forms were obtained again, and medical records were abstracted for 598 women to obtain
the details regarding complete course of treatment for the first primary breast cancer
diagnosis. These data were then compared with the self-reported information obtained
during the telephone follow-up interview. Kappa coefficients comparing self-report and
medical records were high for all three treatment modalities examined: radiation therapy
κ=0.97, chemotherapy κ=0.96 and hormone therapy κ=0.92,21 and thus the self-reported
data are included in these analyses. Data on tumor size were obtained from the New York
State Cancer Registry.
Statistical Analysis
Non-response to specific questions among subjects alive at each time, coupled with non-
participation in the follow-up interview, yielded missing data on weight (48%, 49% and
34% at time of diagnosis, 1-year post diagnosis and final follow-up, respectively). Given
such substantial missing data, and the sensitivity of assessing body size, there was concern
that body size data may be not missing at random, a condition that arises when the
probability that data are missing is dependent upon the unobserved values.22,23 In this study,
the potential issue was that non-response to the follow-up questionnaire may be more likely
among heavier women, who may be more psychologically sensitive to questions regarding
bodyweight or who may be in poor health caused by being overweight. To address this
issue, we used a selection model for proportional hazards regression with non-ignorably
missing time-varying covariates.15 The selection model describes the joint distribution of the
probability that covariate data is missing (indicated by the vector of binary variables R), the
outcome (failure time, denoted by T) and the covariates with missing data (denoted by the
vector Z), some of which may vary over time, with fully-observed covariates (denoted by
X). This joint distribution is expressed as a sequence of conditional distributions:
which is used to derive the likelihood.
The probability that data were missing for weight change at each observation, p(R | T, Z, X),
was modeled as a logistic regression with age, weight change at the corresponding
observation, and missingness indicators for previous observations as predictors. Note that
the inclusion of the value of weight change in this model accounts for the potentially not
missing-at-random nature of the data.
For the distribution of the outcome, p(T | Z, X), a proportional hazards regression with time-
varying covariates was specified to estimate the effect of post-diagnosis weight change on
time to death. Values for post-diagnosis weight change between assessed time points (e.g.
years 2, 3 and 4) were approximated by linear interpolation.15 This model included post-
diagnosis change in body size, and was adjusted for age (continuous), chemotherapy (yes,
no), tumor size (>= 2 cm vs. < 2cm), estrogen-receptor status (ER status; yes, no) and
progesterone-receptor status (PR status; yes, no) -- all of which are confounders that
identified through use of a directed acyclic graph. We present models with and without
adjusting for pre-diagnosis body size, BMI one year before diagnosis (<25 kg/m2 (referent
category), >= 30 kg/m2) and adult weight change from age 20 (> 3 kg loss, maintained
within 3 kg (referent category), > 3 kg gain).
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The distribution of change in body size at each time, p(Z | X), was modeled as a linear
regression dependent upon previous change in body-size variables, as well as age,
chemotherapy, menopausal status and BMI before diagnosis variables established in the
literature to be consistently associated with post-diagnosis weight change.2–7 In addition to
weight change, other covariates with relatively high levels missing data included
chemotherapy, tumor size, ER status and PR status, with 32.2%, 31.6%, 34.0% and 34.3%
missing, respectively. Chemotherapy and tumor size were modeled as logistic regressions
against age, income (< $20,000; $20,000–49,999; $50,000–89,999 and >= $90,000) and
education (high school or less, some college, college graduate and post-college), while
hormone receptor status indicators were modeled as logistic regressions as a function of age.
Treatment and tumor characteristics were unlikely to be non-ignorably missing and therefore
did not require specification of models for their missing data mechanisms.
To assess effect modification, the product of post-diagnosis weight change and menopausal
status (premenopausal, postmenopausal), time (< 2 years, >= 2 years), BMI one year before
diagnosis (categorized as <25 kg/m2 and >= 25 kg/m2) and adult weight gain from age 20
years to 1 year before diagnosis (any loss or maintain within 3 kg, gain >= 3 kg) were
included. The time interaction of two years was chosen because recent studies of post-
diagnosis weight change assessed women at approximately this time11,12 and to distinguish
the possible effects of weight gain shortly after diagnosis.
The ancillary models (p(R | T, Z, X) and p(Z| X)) are not of inferential interest and are
needed only to provide unbiased estimates of the survival model. Subjects with minor
amounts of missing data (menopausal status: 2% missing, pre-diagnosis BMI: 1% missing,
adult weight change: 1.2% missing, education: <1% missing) and income: <1% missing)
were excluded from the analysis, as these data were unlikely to influence our results. This
analysis ultimately included 1,436 women, 292 of whom died during our follow-up, with
156 of these deaths attributed to breast cancer.
We employed a fully Bayesian approach to parameter estimation using the Gibbs sampler in
WinBUGS 1.424 to sample from the joint posterior distribution of the parameters. We
specified vague prior distributions: normal with mean 0 and variance 106 for regression
coefficients, gamma with shape and inverse scale parameters of 0.001 for baseline hazards
and variance parameters to generate posterior estimates that are similar to those from
frequentist analysis. The sampler was run for 200,000 iterations, discarding the first 100,000
as a burn-in sample, retaining every 5th iteration to reduce serial correlation. Posterior
hazard ratios (HR) and 95% posterior credible intervals were calculated by taking the anti-
logarithm of the mean of the samples for the beta coefficients (log-hazard ratios) from the
proportional hazards model and the 2.5th and 97.5th percentiles of these samples,
respectively.
Results
Median follow-up time was 8.8 years after diagnosis with a range from 0.2 to 9.4 years. At
the time of diagnosis, the age range of the women was between 25 to 98 years, with an
average of 59 years, and most were postmenopausal (Table 1). Fewer than half of the
women received chemotherapy treatment, and most tumors were hormone-receptor positive.
Fewer than 20% of the tumors were 2 cm or larger. Among women with complete data on at
least one follow-up measure of body size, 55% maintained their pre-diagnosis body size.
Mortality was increased for women who either lost or gained weight after diagnosis (Table
2). The association of moderate weight gain with mortality (all-cause posterior HR = 1.09
[95% credible interval = 0.51 – 2.18]) was somewhat greater after adjustment for pre-
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diagnostic BMI and adult weight gain, and similar to the minimally adjusted model we
reported previously.15 These additional adjustments did not meaningfully change the
observation, from our previous model, that mortality risk was more than doubled for large
post-diagnosis weight gain (all-cause posterior HR= 2.67 [1.37–5.05]); breast-cancer-
specific posterior HR=2.84 [1.15–6.65]) (Table 2). Among women who lost weight after
diagnosis, the effect on survival was adverse; the estimates for all-cause (5.29 [3.48–8.09])
and breast-cancer-specific mortality (7.09 [3.93–13.4]) were similarly pronounced, even
after adjusting for weight changes throughout adulthood but before diagnosis.
As shown in Table 3, the association between weight gain and survival appeared somewhat
stronger among women who were premenopausal before diagnosis (all-cause posterior
HR=2.29 [0.84–6.73]) compared with postmenopausal women (1.51 [0.77–2.87]). The
deleterious effects of post-diagnosis weight gain appear stronger when weight is gained
shortly after diagnosis (within the first 2 years after diagnosis, all-cause posterior HR=5.87
[0.89–47.8] and breast cancer-specific HR=3.75 [0.56–31.2]), although the wide credible
intervals indicate imprecise estimates resulting from the low number of deaths (52 all-cause,
36 breast-cancer-specific) within the first 2 years. Weight gain after two years shows similar
effects for all-cause and breast cancer-specific mortality, with moderate increases in risk of
death compared with women who maintained their weight. The effect of weight gain is
greater among women who were overweight and obese (BMI >= 25 kg/m2) before diagnosis
than among women of ideal weight (BMI < 25 kg/m2) before diagnosis, with the difference
being greatest for breast cancer-related deaths (BMI < 25 kg/m2, posterior HR=1.08 [0.34–
3.21] and BMI >= 25 kg/m2, 2.76 [0.94–8.47]). The effect of weight gain on all-cause
mortality may be limited to those women who gained weight before diagnosis (<3 kg gain
before diagnosis, posterior HR=1.07 [0.30–3.37] and >=3 kg gain before diagnosis, 1.80
[0.99–3.26]). Due to the small number of breast-cancer-related deaths among women
without pre-diagnosis weight gain (n=21), we were unable to calculate stable estimates of
risk of breast-cancer-related mortality associated with post-diagnosis weight change in this
subgroup. However, upon limiting the analysis to women who gained at least 3 kg before
diagnosis, we observed a strong effect of post-diagnosis weight gain (HR=2.24 [0.97–5.26]),
which was similar in magnitude to that observed for all-cause mortality.
Discussion
Previously reported findings on weight change after diagnosis in this cohort of 1,436 women
diagnosed with in situ or invasive breast cancer focused on the methodologic approach for
considering missing covariate data in survival analysis.15 That previous analysis did not
include adjustments for pre-diagnosis levels of BMI or adult weight change, nor did it
consider effect measure modification, including how the effect may vary over time. In the
analysis presented here, even after adjusting for pre-diagnosis body size, moderate increases
in risk of all-cause mortality were still observed among women who gained between 5% and
10% of their pre-diagnosis weight at any time after diagnosis. Large increases in mortality
risk were found among women who gained more than 10% of their pre-diagnosis weight
after diagnosis. When pre-diagnosis anthropometric measures of adiposity were included in
the models, the effects were essentially unchanged. The effect of weight gain on mortality
appeared stronger among premenopausal women compared with postmenopausal women
and for women within the first 2 years after diagnosis compared with after 2 years, although
analytic precision was limited to draw firm conclusions regarding these differences. The
effect of post-diagnosis weight gain on breast-cancer-specific mortality was also stronger
among women who had gained weight as an adult before diagnosis.
Fat mass may promote the development of postmenopausal breast cancer because visceral
adipose tissue is metabolically active25 and affects a number of pathways that are involved
Bradshaw et al. Page 6













in carcinogenesis. Visceral adipose tissue is associated with increased estradiol and
decreased sex hormone binding globulin (SHBG),26 as well as increased insulin and insulin-
like growth factors,10,27 which can promote a hormonal environment that encourages
proliferation of both normal and cancerous mammary cells.8–10 Weight gain after
adolescence is associated with accumulation of visceral adipose tissue, and therefore
changes in body size may be relevant.28 Similar biologic effects of increasing levels of
adipose tissue on prognosis are of particular concern, as weight gain from approximately 1
kg to more than 10 kg within the first two years after diagnosis of breast cancer is well-
documented.4
The relationship between breast cancer survival and post-diagnosis weight change is far less
studied than the relationship with pre-diagnostic body size.11–14,29–33 Although the
methodology varied considerably among previous studies, findings in general for
postdiagnostic weight gain have been null when modest increases in weight have been
considered, with mean weight gain of less than 6 kg in the upper category.31–33 However,
greater increases in mortality have been noted with larger changes in weight or BMI,
particularly in subgroups,12,29,30 with mean weight change among subjects in the upper
category typically over 10 kg. Recent findings for postdiagnostic weight gain remain
inconsistent; Caan and colleagues11 failed to find an association between post-diagnosis
weight change and survival, yet Nichols et al.13 found results more similar to those reported
here. Most recently, in a Chinese cohort, Chen et al.14 reported that weight gain of 5 kg or
more during the 18 months after diagnosis was associated with poor survival, and the effect
was slightly stronger for breast-cancer-specific mortality.
Differences in findings related to postdiagnostic weight gain across studies are therefore
likely due to variations across studies in the study cohort (years since the first primary
diagnosis, ethnicity, age/menopausal status of the patients, sample size, and length of
follow-up), and in the exposure measure (number of weight assessments, and the average
weight gained postdiagnosis). For example, studies with null findings have been limited by
small sample sizes31–33 and short follow-up.31,33 Timing of the post-diagnostic weight
change measures is also likely to contribute to varied findings. Unlike previous work, our
study was able to utilize multiple anthropometric measures from date of diagnosis, allowing
us to estimate the effect of this time-varying exposure, as well as to estimate differences in
effect across relevant time periods. Our findings of a possible stronger association of post-
diagnosis weight gain among premenopausal women is supported by some other studies12,29
but not all.13,14 The very different study populations in the latter reports (a Chinese cohort in
one,14 only non-metastatic cases interviewed one to two years after diagnosis in the other13)
could explain this discrepancy. We found the effect of weight gain was more pronounced
closer to diagnosis, which was not assessed in other studies that instead used body size
measures at least 2 years following diagnosis.11,12 The lone previous study that did assess
weight change near and after diagnosis14 analyzed weight change only as a series of fixed
time exposures, which fails to account for the longitudinal aspect of this variable.
Our findings of greater mortality associated with postdiagnostic weight loss are consistent
with recent reports,11,13,14 which all report hazard ratios over 2 in the greatest category of
weight loss for death from any cause. Data from the Nurses’ Health Study also suggested a
greater risk of death among those who lost weight, although this finding was not statistically
significant.12 It is unclear if this observed association between weight loss and survival is
due to a distinct effect of the weight loss or to the fact that those who are near death are
likely to be losing weight. This issue could possibly be clarified by studies with larger
sample size that assessed intent of weight loss. Recent recommendations regarding weight
loss for breast cancer patients34 have been made based on the observation that greater BMI
at diagnosis is associated with poor survival. However, these recommendations may be
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premature, given that they are not consistent with the currently available epidemiologic
evidence, including the study reported here.
Obesity at diagnosis and adult weight gain before diagnosis are established indicators of
poorer prognosis,4,34–36 although most of the studies conducted to date have not accounted
for post-diagnosis changes in body size. Similarly, a recent report that utilized the Long
Island breast cancer cohort observed hazard ratios ranging from 1.63 to 2.85 for women who
were obese before diagnosis.21 Additionally, our observation of a more pronounced adverse
effect for post-diagnosis weight gain among women who also gained weight as an adult
before diagnosis underscores the importance of avoiding increases in adiposity at any point
in a woman’s life trajectory.
Strengths of this study include its population-based study design and relatively large sample
size. Also, an innovative analytic approach to the treatment of missing exposure and
confounder data was employed. A commonly used alternative approach is the complete case
analysis, which is automatically carried out by most software packages; however, it usually
reduces statistical efficiency, and can yield biased effect estimates in all but the most rigid
conditions. Ad hoc adjustment for missing data is still common in epidemiology -- such as
some variant of the “missing indicator” method or improper imputation, which can perform
even worse than complete case analysis.22 Formal treatment of missing data is crucial to
accurate inference, and the selection model approach employed here can account for
potentially non-ignorably missing covariates, which is a situation where bias and statistical
efficiency are of greatest concern.23 Even though the methodology used here is theoretically
sound, it is important to keep in mind that even the most rigorous statistical model is no
substitute for having the data that were unobserved. Missing-data models rely on untestable
assumptions and can be quite sensitive to changes in specification.37
An important strength of this analysis is that data from multiple assessments of change in
body size over the follow-up experience were utilized, starting at and near diagnosis, which
allowed for determination of differential effects based on timing of weight change – an
assessment that until now has not been addressed. A limitation of this analysis is the use of
self-reported body size measures, which leaves open the potential for measurement error.
However, self-reported anthropometric measures have been shown to be highly correlated
with measurements taken in a clinic setting.38 Data from the NHANES III study showed that
self-reported and measured weight are highly correlated and that older women, who make
up most of this cohort, tend to report their weight accurately.39 Also, self- and interviewer-
obtained measurements have shown nearly identical associations in a recent analysis of pre-
diagnosis BMI and survival after breast cancer diagnosis in a similar cohort.40 The use of
proxy interviews could also be a source of bias, although these accounted for only a small
portion of our study sample (<8%), and a recent detailed report comparing the use of proxy
and case assessments illustrated that proxy assessments of anthropometric measures yielded
associations that were nearly identical to those completed by the case subject.41 To address
this concern, we conducted a sensitivity analysis omitting those subjects with data from
proxy interviews with similar results (data not shown).
The results from our stratified models should be interpreted as exploratory given that
statistical precision was reduced for subgroup analysis. The categorization of pre-diagnosis
BMI and pre-diagnosis weight gain yielded a different percentage of cases in each subgroup.
Notably 80% of the cohort appeared in the upper category of pre-diagnosis weight gain,
which may have contributed to the differences noted, as BMI and weight gain are highly
correlated.
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In summary, these findings suggest that weight maintenance after breast cancer diagnosis
should be encouraged, especially among women who have gained weight as an adult before
diagnosis. The time period immediately after diagnosis may be especially relevant for
weight maintenance, when treatment-related weight gain is common.
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Table 1
Characteristics of 1,436 women newly diagnosed with a first primary breast cancer between 1996 and 1997 on
Long Island, NY, with follow-up assessments between 2002 and 2004.
Variable no. (%)
Deaths through December 31, 2005
     All causes 292 (20)
     Breast-cancer 156 (11)
     Weight change from 1-year before diagnosis to date of diagnosis
     >5% loss 197 (26)
     Maintain ±5% 458 (60)
     5–10% gain 72 (10)
     >10% gain 31 (4)
     Missing 678
To 1-year after diagnosis
     >5% loss 168 (23)
     Maintain ±5% 400 (55)
     5–10% gain 95 (13)
     >10% gain 64 (9)
     Missing 709
To time of follow-up interview
     >5% loss 200 (21)
     Maintain ±5% 414 (44)
     5–10% gain 161 (17)
     >10% gain 168 (18)
     Missing 493
Estrogen receptor status
     Positive 701 (74)
     Negative 252 (26)
     Missing 483
Progesterone receptor status
     Positive 609 (64)
     Negative 340 (36)
     Missing 487
Chemotherapy
     Yes 404 (41)
     No 573 (59)
     Missing 459
Tumor size
     < 2 cm 749 (76)
     >= 2 cm 234 (24)
     Missing 453
BMI 1 year before diagnosis (kg/m2)
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Variable no. (%)
     <18.5 25 (2)
     18.5–24.9 639 (45)
     25.0–29.9 455 (32)
     >=30.0 317 (22)
Weight change from age 20 to 1 year before diagnosis
     < 3 kg gain or any loss 240 (17)
     > 3 kg gain 1196 (83)









Menopausal Status at diagnosis
     Premenopausal 462 (32)
     Postmenopausal 974 (68)
Education level at diagnosis
     High school or less 688 (48)
     Some college 342 (24)
     College graduate 186 (13)
     Post college education 220 (15)
Income at diagnosis
     < $20,000 174 (12)
     $20,000–49,999 560 (39)
     $50,000–89,999 427 (30)
     >=$90,000 275 (19)
a
(mean=58.8 yrs [sd=2.6 yrs])
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Table 2
Hazard ratios (and 95% credible intervals) for the association between post-diagnosis changes in body weight
and all-cause and breast cancer-specific mortality among women newly diagnosed with a first primary breast
cancer in 1996–1997 in Long Island, NY and followed through 2005.










     >5% loss 5.30 (3.54–8.04) 5.29 (3.48–8.09) 7.25 (4.06–13.4) 7.09 (3.93–13.4)
     ±5% maintaine 1.00 1.00 1.00 1.00
     5–10% gain 1.08 (0.51–2.15) 1.09 (0.51–2.18) 0.84 (0.24–2.46) 0.85 (0.24–2.46)
     >10% gain 2.72 (1.40–5.09) 2.67 (1.37–5.05) 2.80 (1.13–6.50) 2.84 (1.15–6.65)
a
292 deaths; 1436 subjects
b
156 deaths; 1436 subjects
c
Model 1 adjusted for age at diagnosis, chemotherapy treatment, ER status, PR status and tumor size. These results presented previously
(Bradshaw et al.15).
d
Model 2 includes covariates from Model 1 as well as BMI 1 year prior to breast cancer diagnosis and weight change from age 20 up to 1 year
before breast cancer diagnosis.
e
Reference category
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Table 3
Hazard ratios (and 95% credible intervals) for the association between post-diagnosis changes in body weight
and all-cause and breast cancer-specific mortality, stratified by menopausal status, time, pre-diagnosis BMI
and pre-diagnosis adult weight change among women newly diagnosed with a first primary breast cancer in




Hazard ratio (95% credible interval)
Breast Cancer-specific Mortalityb
Hazard ratio (95% credible interval)









>5% loss 9.16 (3.67–26.3) 4.92 (3.14–7.88) 9.90 (3.34–34.4) 6.47 (3.24–13.7)
±5% maintaind 1.00 1.00 1.00 1.00
>5% gain 2.29 (0.84–6.73) 1.51 (0.77–2.87) 3.09 (0.99–11.2) 0.89 (0.24–2.81)









>5% loss 15.00 (3.53–99.48) 5.21 (3.41–8.06) 10.64 (2.39–71.7) 7.11 (3.77–14.0)
±5% maintaind 1.00 1.00 1.00 1.00
>5% gain 5.87 (0.89–47.8) 1.49 (0.85–2.57) 3.75 (0.56–31.2) 1.48 (0.62–3.44)









>5% loss 7.43 (4.09–14.1) 4.75 (2.80–8.41) 7.98 (3.51–19.0) 7.84 (3.36–21.2)
±5% maintaind 1.00 1.00 1.00 1.00
>5% gain 1.39 (0.62–3.01) 1.91 (0.91–3.88) 1.08 (0.34–3.21) 2.76 (0.94–8.47)









>5% loss 4.18 (1.62–10.8) 6.06 (3.88–9.70) --- 8.78 (4.51–18.0)
±5% maintaind 1.00 1.00 --- 1.00











Small number of events in this subgroup (n=21) precluded stable effect estimates.
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